title: Will public health survive QALYs?
authors.affiliation: James G Heller Consulting Inc., Toronto, Canada. jgheller@jghcons.com
authors.forename: James G
authors.initials: JG
authors.lastname: Heller
mesh_terms: D002170:Canada; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D007155:Immunologic Factors / Q000191:economics / Q000627:therapeutic use; D016899:Interferon-beta / Q000191:economics / Q000627:therapeutic use; D008962:Models, Theoretical; D009103:Multiple Sclerosis / Q000188:drug therapy; D011634:Public Health; D019057:Quality-Adjusted Life Years
chemical_list: D007155:Immunologic Factors; D016899:Interferon-beta